{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:21:10Z","timestamp":1786116070814,"version":"build-2736575974"},"reference-count":69,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Merck, Sharp & Dohme, LLC"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,3,28]]},"DOI":"10.1080\/14796694.2026.2639738","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:34:18Z","timestamp":1773398058000},"page":"939-952","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The broad societal value of pembrolizumab for women\u2019s cancer in Canada"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8180-6368","authenticated-orcid":false,"given":"Elizabeth","family":"Brook","sequence":"first","affiliation":[{"name":"Inizio Ignite Putnam","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4423-0098","authenticated-orcid":false,"given":"Karl","family":"Patterson","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishini","family":"Wijenayake","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Madin-Warburton","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Mishkin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Meilleur","sequence":"additional","affiliation":[{"name":"Merck Canada Inc","place":["Kirkland, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0184-8618","authenticated-orcid":false,"given":"Annabelle","family":"Davies","sequence":"additional","affiliation":[{"name":"MSD (UK) Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-9871","authenticated-orcid":false,"given":"Kate","family":"Young","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00310-y"},{"key":"e_1_3_9_3_1","unstructured":"World Health Organization (WHO). Breast cancer. 2023 [cited 2024 Jul 18]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"e_1_3_9_4_1","unstructured":"Breast cancer UK. About breast cancer: facts and figures. 2024 [cited 2024 Jul 18]. Available from: https:\/\/www.breastcanceruk.org.uk\/about-breast-cancer\/facts-figures-and-qas\/facts-and-figures\/#:~:text=Global%20breast%20cancer%20statistics deaths%20among%20women%20(1)"},{"key":"e_1_3_9_5_1","unstructured":"World Health Organization (WHO). Cervical cancer. 2024 [cited 2024 Jul 18]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer"},{"key":"e_1_3_9_6_1","unstructured":"European Society for Medical Oncology (ESMO). Latest data indicate new care standard in advanced\/recurrent endometrial cancer: results from the RUBY trial. [ESMO press release]. 2023 [cited 2024 Jul 18]. Available from: https:\/\/www.esmo.org\/newsroom\/press-and-media-hub\/esmo-media-releases\/latest-data-indicate-new-care-standard-in-advanced-recurrent-endometrial-cancer-results-from-the-ruby-trial"},{"key":"e_1_3_9_7_1","unstructured":"Government of Canada. Breast cancer. 2024 [cited 2024 Aug 8]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/chronic-diseases\/cancer\/breast-cancer.html"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240095"},{"key":"e_1_3_9_9_1","unstructured":"The World Bank. Canada - gender data portal. 2023 [cited 2024 Jul 26]. Available from https:\/\/genderdata.worldbank.org\/en\/economies\/canada#:~:text=In%20Canada%2C%20the%20labor%20force males%20is%2069.3%25%20for%202023"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/08465371241246422"},{"key":"e_1_3_9_11_1","unstructured":"Canada S. Labour force characteristics by age group monthly seasonally adjusted 2024. [cited 2024 Aug 6]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1410028702"},{"key":"e_1_3_9_12_1","unstructured":"Statistics Canada. Labour force characteristics by age group monthly seasonally adjusted 2024. Table: 14-10-0287-02. [cited 2024 Aug 8]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410028702&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=3.3&cubeTimeFrame.startMonth=06&cubeTimeFrame.startYear=2024&referencePeriods=20240601%2C20240601"},{"key":"e_1_3_9_13_1","unstructured":"Cancer Research UK. Breast cancer incidence (invasive) statistics - breast cancer incidence by age. [cited 2024 Jul 24]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive#heading-One"},{"key":"e_1_3_9_14_1","unstructured":"British Columbia Guidelines. Genital Tract cancers in females: endometrial cancer. 2023 [cited 2024 Aug 6]. Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/bc-guidelines\/endometrial-cancer"},{"key":"e_1_3_9_15_1","unstructured":"York health Economics consortium (YHEC). Glossary; perspective. 2016 [cited 2023 Jun 30]. Available from: https:\/\/yhec.co.uk\/glossary\/perspective\/"},{"key":"e_1_3_9_16_1","unstructured":"Creighton H Beach B Bamford S-M. Rethinking cancer. The big \u2018C\u2019: quantifying the social and economic impact. [cited 2023 Jun 30]. Available from: https:\/\/workingwithcancer.co.uk\/wp-content\/uploads\/2013\/03\/Rethinking_Cancer_-_The_big_C.pdf"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31392-7"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02109-2"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.04.008"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2024-0014"},{"key":"e_1_3_9_22_1","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Methods and guidelines: guidelines for the economic evaluation of health technologies: Canada 2017. [cited 2024 Feb 19]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0082"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.674"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2311507"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00311-5"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02365-1"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"e_1_3_9_31_1","unstructured":"Statistics Canada. Retirement age by class of worker annual 2023. Table 14-10-0060-01. [cited 2024 Mar 19]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410006001&pickMembers%5B0%5D=4.3&cubeTimeFrame.startYear=2023&cubeTimeFrame.endYear=2023&referencePeriods=20230101%2C20230101"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.25318\/1410004301-eng"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01913-5"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1542520"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05654-x"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnss.2020.07.012"},{"key":"e_1_3_9_37_1","unstructured":"Government of Canada. Canada\u2019s health care system. 2019 [cited 2023 Jun]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/health-care-system\/reports-publications\/health-care-system\/canada.html"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.03.006"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13571516.2011.584428"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00780"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs512"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1394"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1031205"},{"issue":"1","key":"e_1_3_9_44_1","first-page":"1","article-title":"Quality of life of caregivers of breast cancer patients: a cross-sectional evaluation","volume":"20","author":"Clarijs ME","year":"2022","unstructured":"Clarijs ME, Oemrawsingh A, Br\u00f6ker ME, et al. Quality of life of caregivers of breast cancer patients: a cross-sectional evaluation. Health Qual Life Outcomes. 2022;20(1):1\u201310.","journal-title":"Health Qual Life Outcomes"},{"key":"e_1_3_9_45_1","unstructured":"Canadian cancer survivor network. Caregivers. 2024 [cited 2024 Mar 19]. Available from: https:\/\/survivornet.ca\/learn\/issues-affecting-cancer-survivors\/personal-experiences-when-dealing-with-cancer\/caregivers\/"},{"issue":"11","key":"e_1_3_9_46_1","first-page":"e368","article-title":"Reconsidering the economic value of multiple sclerosis therapies","volume":"22","author":"Shih T","year":"2016","unstructured":"Shih T, Wakeford C, Meletiche D, et al. Reconsidering the economic value of multiple sclerosis therapies. Am J Manag Care. 2016;22(11):e368\u2013e374.","journal-title":"Am J Manag Care"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.06.021"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.028"},{"issue":"2","key":"e_1_3_9_49_1","first-page":"1","article-title":"The option value of innovation","volume":"15","author":"Snider J","year":"2012","unstructured":"Snider J, Romley J, Vogt W, et al. The option value of innovation. Forum Health Econ Policy. 2012;15(2):1\u201319.","journal-title":"Forum Health Econ Policy"},{"issue":"10","key":"e_1_3_9_50_1","first-page":"e340","article-title":"The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma","volume":"23","author":"Thornton Snider J","year":"2017","unstructured":"Thornton Snider J, Batt K, Wu Y, et al. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma. Am J Manag Care. 2017;23(10):e340\u2013e346.","journal-title":"Am J Manag Care"},{"key":"e_1_3_9_51_1","unstructured":"National institute for health and care excellence (NICE). NICE health technology evaluations: the manual. 2022 Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"e_1_3_9_52_1","unstructured":"Statistics Canada. Life expectancy and other elements of the complete life table three-year estimates Canada all provinces except Prince Edward Island (table: 13\u201310-0114\u201301). 2022 [cited 2024 Mar 13]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011401"},{"key":"e_1_3_9_53_1","unstructured":"Hern\u00e1ndez Alava M Pudney S Wailoo A. ESTIMATING EQ-5D BY AGE AND SEX FOR THE UK - REPORT BY THE DECISION SUPPORT UNIT. 2022 [cited 2024 Feb 28]. Available from: https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/DSU%20Age%20based%20utility%20-%20Final%20for%20website.pdf"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200245"},{"key":"e_1_3_9_55_1","unstructured":"Quebec. Medically assisted reproduction program 2024. [cited 2024 Mar 19]. Available from: https:\/\/www.quebec.ca\/en\/family-and-support-for-individuals\/pregnancy-parenthood\/assisted-reproduction\/medically-assisted-reproduction-program"},{"key":"e_1_3_9_56_1","unstructured":"Ontario Canada. Get fertility treatments. [cited 2024 Apr 16]. Available from: https:\/\/www.ontario.ca\/page\/get-fertility-treatments"},{"key":"e_1_3_9_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54961-6"},{"key":"e_1_3_9_58_1","unstructured":"York Health Economics Consortium (YHEC). Glossary; perspective 2016. Available from: https:\/\/yhec.co.uk\/glossary\/net-health-benefit\/"},{"key":"e_1_3_9_59_1","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Approval of pembrolizumab for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer. 2023 [cited 2023 Aug]. Available from: https:\/\/www.cadth.ca\/pembrolizumab-7"},{"key":"e_1_3_9_60_1","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Approval of pembrolizumab as monotherapy for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer. 2023 [cited 2023 Aug]. Available from: https:\/\/www.cadth.ca\/pembrolizumab-8"},{"key":"e_1_3_9_61_1","unstructured":"Canada\u2019s Drug Agency (CDA-AMC). Guidelines for the economic evaluation of health technologies: Canada \u2014 4th edition. 2021 [cited 2024 Sep 23]. Available from: https:\/\/www.cda-amc.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition"},{"key":"e_1_3_9_62_1","unstructured":"Oosthuizen Jea. Reimagining cancer care: the potential of timely and early intervention. 2021 [cited 2024 Aug 20]. Available from: https:\/\/www.globalgovernanceproject.org\/advocacy-reimagining-cancer-care-the-potential-of-timely-and-early-intervention\/jannie-oosthuizen\/"},{"key":"e_1_3_9_63_1","unstructured":"Canada\u2019s Drug Agency (CDA-AMC). Piloting the addition of new perspectives to economic evaluations of drugs. 2024 [cited 2024 Aug 8]. Available from: https:\/\/www.cadth.ca\/news\/piloting-addition-new-perspectives-economic-evaluations-drugs"},{"key":"e_1_3_9_64_1","unstructured":"(INESSS) Indeeseess. Lignes directrices d\u2019\u00e9valuation \u00e9conomique des interventions en sant\u00e9 et en services sociaux \u00e0 l\u2019INESSS r\u00e9dig\u00e9 par Sylvie Arbour et Caroline Cambourieu Qu\u00e9bec Qc2025. [cited 2025 Jun]. Available from: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/DocuMetho\/Evaluation_economique_LD_INESSS.pdf"},{"key":"e_1_3_9_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01316-0"},{"key":"e_1_3_9_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1334842"},{"key":"e_1_3_9_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01164-4"},{"key":"e_1_3_9_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01246-x"},{"key":"e_1_3_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.010"},{"key":"e_1_3_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.06.011"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2639738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2639738","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2639738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:40:56Z","timestamp":1786002056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2639738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,3,28]]}},"alternative-id":["10.1080\/14796694.2026.2639738"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2639738","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}